Obesity, particularly its abdominal phenotype, a harbinger of the metabolic syndrome, cardiovascular diseases (CVDs) and type 2 diabetes mellitus (T2D), is becoming one of the most significant public health problems worldwide. Among many other potential factors, derangement of multiple hormone systems have increasingly been considered for their potential importance in the pathophysiology of obesity and the metabolic syndrome, with particular reference to glucocorticoids and sex hormones. These systems have a fundamental and coordinating role in the physiology of intermediate metabolism and cardiovascular function, and in the response to acute and chronic stress challenge. Abdominal obesity is associated with a hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis and impaired androgen balance, although these alterations differ according to sex. As there is also increasing evidence that there are many differences between the sexes in the susceptibility and development of obesity, T2D and CVDs, we support the hypothesis that alterations of the HPA axis and androgen balance may have an important function in this context. This is further supported by the fact that there are important differences between males and females in their ability to adapt to both internal and particularly to environmental (external) stressors. In addition, there is also evidence that, in both physiological and pathological conditions, a close cross talk exists between sex hormones and glucocorticoids at both neuroendocrine and peripheral level, again with different specificities according to sex.
Introduction
Obesity, particularly its abdominal phenotype, a harbinger of the metabolic syndrome, cardiovascular diseases (CVDs) and type 2 diabetes (T2D), is becoming one of the most significant public health problems worldwide. 1 Classic factors responsible for this epidemic include unhealthy lifestyle behaviour, specifically sedentary activity and excess dietary habits, with particular reference to high fat and/or carbohydrate intake. 2 In addition, there is evidence that environmental stress factors may have an independent function in increasing individual susceptibility towards these diseases. 3 Pathophysiological events responsible for the association between obesity and metabolic or cardiovascular dysfunctions have been extensively investigated in the last two decades, with particular emphasis on insulin resistance and, more recently, on the function of the low-grade inflammation, which can induce insulin resistance. This in turn can lead to clinical and biochemical manifestations of the metabolic syndrome, chiefly abdominal obesity and an atherogenic lipid profile, 4 although a vicious circle may take place, as resistance to insulin action on its own promotes inflammation further through an increase in free fatty acids concentration and an interference with the anti-inflammatory effect of insulin. 5 Among other factors, modified multiple hormone systems have increasingly been considered for their potential significance in the pathophysiology of obesity and the metabolic syndrome, with particular reference to glucocorticoids and sex hormones. 6, 7 These systems in fact have a fundamental and coordinating role in the physiology of intermediate metabolism and cardiovascular function. Table 1 shows the main alterations of these endocrine systems in obese males and females. The metabolic aspects of glucocorticoid action and regulation have been particularly investigated in the insulinsensitive tissues and brain. 21 Classic disorders of altered glucocorticoid and sex hormone production have been recognized for a long time as being responsible for the development of obesity, insulin resistance, dyslipidemia and cardiovascular abnormalities. 8 In addition, research has also been focused on the role of glucocorticoids in the response to stress stimuli and consequent whole body adaptative behaviour. In fact, since the pioneering work by Per Bjorntorp, the concept has spread that obesity, particularly the abdominal phenotype, and the metabolic syndrome may be the consequences of an individual maladaptation to chronic environmental stress exposure mediated by a dysregulation of related neuroendocrine axes, responsible for hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic nervous system (SNS). 13 Another recent area of interest is represented by the role of glucocorticoids in stress-induced food intake, a topic previously underappreciated, and on the model including the chronic indirect metabolic feedback effect of glucocorticoids at the central brain neuroendocrine systems, proposed by Dallman et al.
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A parallel increasing interest has emerged regarding the role of sex hormones, particularly androgens, in the pathophysiology of obesity and the metabolic syndrome as well as of T2D. Obesity is associated with a considerable derangement of androgen production and metabolism, and available evidence provided by animal and human studies suggests that this may have a function in favouring the development of abdominal obesity, particularly in women, and in decreasing whole body insulin sensitivity. 9 Notably, however, there is also increasing evidence that there are many differences between the sexes in the susceptibility and development of chronic metabolic disorders and CVDs, which implies that mechanisms may partly differ in males and females, involving both endogenous and exogenous factors. Fundamental differences in the biology of sex differences primarily involve sex hormones, which define the differentiation of secondary sex characteristics at puberty, regulate fertility, metabolism and behaviour and have an important function in regulating many functions of various non-reproductive tissues. 23 Androgens are fundamental examples of this sex-related hormonal function.
They have different functions with typical genomic influences on protein synthesis mediated by transcription induced as a result of the binding of hormones to intracellular receptors and DNA, and by means of these actions, they regulate vascular function, as well as body composition and fat metabolism. 23 Changes in the androgen balance have been found to be associated with a series of chronic metabolic disorders and CVDs, with different mechanisms according to sex. 8 Among many other functions and factors defining biological sex differences, another important difference between males and females is represented by the ability to adapt to both internal and particularly to environmental (external) stressors, which may have some relevance in influencing the onset and evolution of metabolic disorders and CVDs according to sex. There is emerging evidence for a distinct quantitative and qualitative response of these hormonal systems according to sex, not only in the maintenance of physiology, but also in the pathophysiological events leading to the development of stress-related chronic diseases. In physiological conditions, a strict cross talk exists between sex hormones and glucocorticoids at both neuroendocrine and peripheral level, with different specificities according to sex. 15 Moreover, clinical disorders of glucocorticoid excess are associated with specific abnormalities and androgen balance, 8 and altered androgen metabolism and production can be associated with hyperactivity of the HPA axis. This review therefore attempts to support the concept that combined dysregulation and function of the corticosteroid and androgen endocrine axes may have a coordinating role in the pathophysiological development of obesity, specifically the abdominal phenotype, and associated metabolic syndrome.
A schematic picture summarizing our working hypothesis is represented in Figure 1 .
Obesity and patterns of fat distribution in males and females
Abdominal obesity is the most important risk factor included in the metabolic syndrome and predisposes to the development of CVDs and particularly T2D. Overweight and obesity are increasing dramatically worldwide, 24 involving approximately half the population. Sex differences in overweight and obesity are clearly influenced by geography and ethnic background. For example, data coming from North America show that the prevalence of overweight and obesity among white and Mexican Americans is higher among men than among women, whereas among black Americans, the prevalence is higher in women than in men. 25, 26 In Europe, the extent of this epidemic appears to be less dramatic. 24 Overweight and obesity are also prevalent in many developing countries, with some geographical and ethnic differences. Collectively, prevalence rates appear to be similar for both sexes, although available data suggest that countries reporting higher levels of overweight among women are located in Africa, Latin America, Asia and Oceania, whereas male overweight and obesity appear to HPA axis response to stress Higher than in men [15] [16] [17] Lower than in women [15] [16] [17] Cortisol production rates in peripheral tissue (due to activity of the 11b-HSD1)
Increased [18] [19] [20] Increased [18] [19] [20] Abbreviations: 11b-HSD1, 11b-hydroxysteroid dehydrogenase type 1; HPA, hypothalamic-pituitary-adrenal.
Role of glucocorticoids and androgens in obesity R Pasquali et al be more prevalent than in women in European and North American countries. 27 The abdominal obesity phenotype has a dominant importance in the definition of the metabolic syndrome. Epidemiology of different fat distribution phenotypes is complicated by the need for anthropometric measurements according to body size and ethnicity, although different cut-off values of waist circumference, according to different populations, have recently been defined. 28 With a larger waist circumference, the prevalence of abdominal visceral fat undoubtedly tends to increase, although mechanistically a distinction between a large waist due to increases in subcutaneous adipose tissue versus visceral fat is still debated, on the basis of imaging studies. 29 However, it is widely accepted that abdominal obesity measured by waist circumference or waist-to-hip ratio (WHR) confers an independent and additional risk for metabolic diseases and CVDs regardless of the degree of obesity. [30] [31] [32] [33] [34] [35] [36] It should be argued that, although abdominal visceral fat has several important differences with respect to subcutaneous abdominal fat, studies on fat metabolism have shown that abdominal subcutaneous fat has specific and distinct features with respect to other subcutaneous fat depots, particularly gluteo-femoral fat. 37 This is particularly significant for women. In fact, whereas there is evidence that obesity in males is invariably associated with a parallel increase in abdominal fat, in women, a clear dichotomy of fat distribution occurs, with approximately one-third of women presenting with the abdominal phenotype. 38 These women have distinct metabolic and hormonal characteristics with respect to those with the subcutaneous peripheral phenotype, such as an increased prevalence of the metabolic syndrome, higher insulin concentrations, higher androgen levels and higher stimulated cortisol concentrations. 9 Metabolic specificities and regulatory factors differentiating visceral fat versus subcutaneous fat in both sexes have been discussed in depth in recent review articles. 9, 38 Abdominal obesity is closely associated with the metabolic syndrome, [39] [40] [41] T2D [42] [43] [44] and cardiovascular risk 45 in both men and women, particularly in those in the postmenopausal period. 46 The association between T2D and different obesity phenotypes in women with respect to men is of particular interest. Studies performed in the 1990s clearly demonstrated that the ageadjusted relative risk for T2D rises with increasing body mass index (BMI) in both men 47 and women. 48 However, more recent studies have repeatedly shown that the prevalence of abdominal obesity was more than 70% in diabetic women compared with approximately 40% in diabetic men [42] [43] [44] ( Figure 2 ). These data indicate that the association between abdominal obesity and T2D is stronger in women than in men, reflecting the need for careful recognition of the abdominal fatness phenotype as a specific target for prevention and possibly for treatment in women. In addition, this may imply some different pathophysiological mechanisms responsible for the development of abdominal obesity in relation to sex. Figure 1 A general hypothesis on the coordinating role of the HPA axis, the SNS and androgens in the development of central obesity and metabolic and cardiovascular comorbidities. Genes, excess diet and unhealthy lifestyle are the main factors responsible for the development of obesity. In addition, chronic stress exposure may favour obesity by increasing allostatic work and developing a poor adaptative syndrome. Sex hormones regulate the response to stress differently in females and males. Obesity per se produces disparate effects on androgen production rates and metabolism according to sex. Increased allostatic work implies overactivation of the HPA axis and the SNS, which in turn further worsen androgen imbalance. The coordinating role of excess cortisol and noradrenergic tone, and low testosterone levels in obese males and high testosterone levels in obese females may therefore have a pathophysiological significance for the development of the abdominal phenotype of obesity and associated metabolic and cardiovascular comorbidities.
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Pathophysiological aspects of abdominal obesity: the HPA axis and androgen imbalance
Steroids have an important function in the regulation of adipose tissue metabolism, with important differences according to its distribution. 8, 18, 38, 49 Alterations of the HPA axis and androgen imbalance may have profound effects on adipose tissue morphology and function. This is discussed in the following sections.
The HPA axis Cushing's syndrome is characterized by a redistribution of adipose tissue from peripheral to the truncal region and visceral depots. This occurs as a result of the dual effect of glucocorticoids, which on the one hand, downregulate HSL and increase lipolysis, and on the other, favour pre-adipocyte differentiation and stimulate substrates to gluconeogenesis and free fatty acids to central fat. 8, 38 In addition, glucocorticoid excess inhibits glucose uptake by peripheral tissues, stimulates gluconeogenesis and increases post-absorptive glucose and insulin. In the insulin-sensitive tissues, glucocorticoids also impair the post-receptor insulin function by mechanisms that involve interaction with glucose transporters. 18, 38, 49 After surgical treatment for the cause of Cushing's syndrome (generally pituitary or adrenal adenomas), centralization of visceral fat depots tends to be markedly reduced, a process that can be successfully completed within 1-2 years. 18 Exogenous glucocorticoid treatment in experimental animals and humans also leads to the development of the abdominal obesity phenotype. 8, 13 Moreover, animal models of obesity invariably have increased levels of corticosterone, and adrenalectomy leads to its reversal. 49 Abdominal obesity and hypercortisolemic syndromes share several similarities, and a hypothetical function of glucocorticoid excess in the pathophysiology of the abdominal obesity phenotype has therefore been hypothesized. 50 These effects, however, may require the concerted action of many other hormones, including increased insulin levels, altered catecholamine regulation, growth hormone reduction and particularly decreased (in males) or increased (in females) free androgen availability. 8 Although research in this area is complicated, many studies have documented that in abdominal obesity, a subtle hyperfunction of the HPA axis may exist, 18 being characterized by a high secretion of cortisol after laboratory stress test, adrenocorticotropin hormone (ACTH) and cortisol overresponsiveness to neuropeptides and secretagogues, and increased free cortisol values in both urine or saliva. 3, 50 Overall, these data suggest a central neuroendocrine dysregulation leading, in turn, to slightly abnormal net cortisol production, either continuous or episodic. Unfortunately, no single available marker, particularly in the basal state, has the power to detect subtle alterations of the HPA axis in these conditions, although evaluation of urinary-free cortisol (UFC), particularly during the night time, and salivary free cortisol appear to be promising for these purposes.
14 Increased cortical production in obesity may also depend on peripheral mechanisms. Higher numbers of glucocorticoid receptors have been demonstrated in visceral than in subcutaneous adipocytes, favouring an increase in intracellular cortisol action in the visceral fat. 51 In addition, alterations of the activity of two enzyme systems, such as impaired activity of 11b-hydroxysteroid dehydrogenase type 1 (11b-HSD1), which reactivates cortisol from inactive cortisone in the liver and the adipose tissue, and enhanced activity of the 5a-reductase, which metabolizes cortisol to its tetrahydroderivates (tetrahydrocortisol and tetrahydrocortisone), have been described in patients with central adiposity. 19, 20, 52 The potential importance of this system has been emphasized by studies demonstrating that transgenic mice selectively overexpressing 11b-HSD1 in the adipose tissue have increased levels of corticosterone and develop visceral obesity, the metabolic syndrome and insulin resistance, 53 whereas those lacking 11b-HSD1 appear to be protected from these alterations. 54, 55 Regulation of 11b-HSD1 expression is under the control of many stimulatory (glucocorticoids, perixosome proliferator-activated receptor-g agonists, tumour necrosis factor-a, interleukin-6 and so on) and inhibiting factors (growth hormone and insulin growth factor 1). 19 In view of the known effects of glucocorticoids on adipose tissue function and distribution, it has been postulated that the enhanced conversion of cortisone to cortisol within the omental tissue may have an important function in the pathogenesis of central obesity. However, adipose tissue-specific expression of 11b-HSD1 in human obesity remains a controversial area. 11b-HSD1 is highly expressed in human adipose tissue, and the levels of expression are similar between omental and subcutaneous depots, although in preadipocytes the expression appears to be higher in omental cells. 19 Cortisol is essential for adipocyte differentiation, and the autocrine generation of cortisol by cortisone is able to regulate this process. Moreover, Mannucci et al. 43 and Marchesini et al., 44 respectively, with permission).
Role of glucocorticoids and androgens in obesity R Pasquali et al increased activity of 11b-HSD1 has been postulated to have a function in regulating insulin sensitivity in the liver, adipose tissue or muscle. 19, 20 Global assessment of 11b-HSD1 has been investigated mainly by means of two methods. Generation of cortisol from an oral dose of cortisone acetate, which is believed to largely reflect hepatic 11b-HSD1 activity, has been found to be impaired in obese patients. 19 The urinary cortisol and cortisone metabolites (tetrahydrocortisol and tetrahydrocortisone) are also believed to reflect global 11b-HSD1 activity. However, some studies have described decreased tetrahydrocortisol þ allo-tetrahydrocortisol/tetrahydrocortisone ratios, consistent with decreased 11b-HSD1 activity with increasing BMI, whereas other studies have failed to show this relationship. 19 However, in all cases, cortisol generation after an oral dose of cortisone has been found to be clearly reduced in simple obesity. Human studies also suggest a reduction in 11b-HSD1 oxoreductase activity in females compared with males, and this may be explained by the differing patterns of fat distribution. 19 Therefore, although animal studies suggest an important function of 11b-HSD1 dysregulation in the pathogenesis of obesity and related metabolic alterations, the hypothesis that human obesity occurs as a consequence of adipose tissue-specific overexpression of this enzyme, and hence of increased tissue-specific cortisol concentrations, has yet to be confirmed. 20 In summary, both neuroendocrine hyperactivity of the HPA axis and peripheral cortisol production can be associated with abdominal obesity.
Androgen imbalance
The increase in fat mass is associated with several abnormalities of sex steroid balance in both sexes and involves alterations of the sex hormone carrier protein, SHBG (sex hormone-binding globulin). Changes in SHBG concentrations lead to an alteration of androgen and oestrogen delivery to target tissues. By inhibiting its synthesis in the liver, insulin has the main responsibility of decreasing SHBG blood levels, although other stimulating and inhibiting factors are involved. 56 In obese women, SHBG levels are inversely related to the increase in body weight. 57 This determines an increase in the production rates and the metabolic clearance rate of circulating SHBG-bound steroids, specifically testosterone, dihydrotestosterone and androstenediol, the principal active metabolite of dihydrotestosterone, 10, 11 and also increases the free fraction of androgens available for target tissues. Notably, obesity in women also affects androgens not bound to SHBG, the production rates and metabolic clearance rates of dehydroepiandrosterone sulphate and androstenedione being equally increased in this condition. 58 Body fat distribution has an additional effect on SHBG concentrations in obese women, and the abdominal phenotype tends to be characterized by lower SHBG levels than the peripheral phenotype, due to increased circulating insulin. 59, 60 Moreover, women with the central phenotype are characterized by a significantly higher production rate of androgens bound to SHBG, 8 which is only partly compensated by an increased metabolic clearance rate, and a condition of 'mild relative hyperandrogenic state' may therefore develop. 9 Owing to the greater reduction of SHBG concentrations, the percentage of free testosterone fraction tends to be higher in women with abdominal than in those with peripheral obesity. 60 In the obese male, total and free testosterone blood concentration levels progressively decrease with increasing body weight, and this reduction is associated with a progressive decrease of SHBG concentrations. 12 Spermatogenesis and fertility are, however, not impaired in the majority of obese men, except in those with massive obesity. 61 Androstenedione and dihydrotestosterone circulating levels are usually normal or slightly reduced. 62 Changes in testosterone metabolism through 5a-reductase activity may also occur in male obesity. However, although reduced levels of the principal metabolites, such as androsterone glucuronide and 5a-androstane-3a,17b-diolglucuronide, have been reported, with very high BMI values, calculation of conversion rates from precursors (testosterone and dehydroepiandrosterone sulphate) was found to depend solely on decreased precursor levels, rather than on altered 5a-reductase activity. 63 Different patterns of fat distribution may have a specific effect on testosterone levels in men, although contrasting data have been reported. Some studies 38, 64 found an association between testosterone and WHR values, whereas others showed no correlation. 65, 66 This suggests that the relationship between sex steroids and WHR may be the result of the shared covariance of WHR and total adiposity, rather than a direct relationship. Other studies confirmed that the reduction of C19 steroid precursors is predominantly associated with body fatness rather than with excess visceral fat accumulation. Glucuronic acid is able to conjugate steroids, influencing their biological activity. Notably, 3-androstenediol glucuronide levels were found, however, to be significantly higher in men with abdominal obesity, 62 which suggests that increased visceral fat corresponds to a state of altered steroid metabolism. Both SHBG and testosterone are negatively correlated with insulin levels, even after adjusting for BMI and WHR values. 38 Abdominal obesity as part of the 'general maladaptation syndrome'
Life exists by maintaining a complex dynamic equilibrium or homoeostasis that is constantly challenged by intrinsic and extrinsic adverse forces, the stressors. When faced with excessive stress, whether physical or emotional, a subject's adaptive responses acquire a relatively stereotypic nonspecific nature, referred to by Selye as 'the general adaptation
Role of glucocorticoids and androgens in obesity R Pasquali et al syndrome'. 67 Stress activates the HPA axis and the SNS. 68 Defence reactions involve release of cortisol and catecholamines, and activate other endocrine systems, such as the renin-angiotension system. 69 In conditions of continuous stress exposure and poor coping, this endocrine activity may be altered, the response to stress is inadequate and compensatory mechanisms are activated; the allostatic load may therefore become overwhelming and the adaptive processes may be maladaptive. 70 Several studies performed in animal models clearly demonstrate that these endocrine alterations may be responsible for metabolic derangements and susceptibility to develop CVDs. An excellent example of these studies is represented by the cynomolgus macaques model, extensively investigated by Shively and Clarkson, 71 who clearly described the sequence of events following long-term exposure to chronic physical and psychological stress. They include enlarged visceral fat, insulin resistance, hyperinsulinemia, impaired glucose tolerance or T2D, adrenal hypertrophy, enhanced cortisol response to ACTH stimulation, hypogonadism, dyslipidaemia and increased incidence of coronary artery atherosclerosis and cardiac events ( Table 2) . Increased HPA axis activity together with activation of the SNS have been related to the individual inability to cope with long-term adverse stressful events during the lifespan. 72, 73 This has been indirectly supported by a long series of epidemiological and clinical studies documenting that abdominal obesity is strongly associated with stress-related or adverse life events and psychosocial conditions, low occupational and educational status, smoking habits, alcohol and/or drug abuse, fat overfeeding, psychiatric disorders, negative personality traits and subjective abnormally perceived stress. [74] [75] [76] Allostatic load has been proposed as a new conceptualization of cumulative biological burden exacted on the body through attempts to adapt to life's demands, therefore referring to the price the body pays for being forced to adapt to adverse environmental stressors. 70 The distinction between protection and damage is related to the dynamics of the hormonal response, involving the HPA axis and the SNS. Using a multisystem summary measurement of the allostatic load (including systolic and diastolic blood pressure, WHR, total and high-density lipoprotein cholesterol, glycosilated haemoglobin, dehydroepiandrosterone sulphate, overnight UFC, overnight urinary norepinephrine and epinephrine), Seeman et al. 77 evaluated its ability to predict health outcomes in a 7-year follow-up survey of 1189 elderly men and women. Higher baseline allostatic load scores were associated with a significantly increased risk for 7-year mortality as well as with declines in cognitive and physical functioning, and were marginally associated with incident CVD events, independent of standard sociodemographic characteristics and baseline health status. Specifically, allostatic load was a better predictor of mortality and decline in physical functioning than the metabolic syndrome. These findings have been extended to other biomarkers, including C-reactive protein, fibrinogen, interleukin-6 and albumin. 78 Overall, these data support the concept that long-term maladaptation to chronic environmental stressors may have an important impact on health, being mediated by the development of abdominal obesity and associated metabolic comorbidities.
Response to stress is part of the biology of human sex difference. It therefore follows that sex hormones are important regulators of individual responses to stress according to sex. Chronic HPA drive and glucocorticoid hypersecretion have been implicated in the pathogenesis of several forms of systemic, neurodegenerative and affective disorders. The HPA axis is subject to gonadal influence, indicated by sex differences in basal and stress HPA function and neuropathologies associated with HPA hyperfunction. 15 In view of the mutual interaction with which the hypothalamic-pituitary-gonadal and HPA systems operate, it is difficult to construct a model showing the action of these hormones in the brain. Manipulation of one endocrine system leads to effects on the other, but their simultaneous manipulation can overcome this problem. Experiments performed using this dual approach in the male rat have revealed that testosterone can interact on different aspects of basal and stress HPA function. Basal ACTH release is in fact regulated by testosterone-dependent effects on arginine vasopressin synthesis, and corticosterone-dependent effects on corticotropin-releasing hormone (CRH) synthesis in the paraventricular nucleus. 79 Moreover, testosterone and corticosterone interact on stress-induced ACTH release and drive to the paraventricular nucleus motor neurones, and the medial preoptic area, central and medial amygdala and bed nuclei of the stria terminalis are candidate structures mediating this interaction.
15
Androgens may also interfere with cortisol metabolism. To support this hypothesis, steroid metabolism was studied in obese and lean male Zucker rats 4 weeks after gonadectomy or sham surgery. 80 Gonadectomy did not consistently alter weight gain, glucose intolerance or insulin in obese animals, Role of glucocorticoids and androgens in obesity R Pasquali et al but only in the presence of obesity did it increase adrenal mass, suppress 11b-HSD1 activity and/or mRNA in liver and adipose, increase 5a-reductase 1 mRNA in liver and increase 5b-reductase activity. Differences in hepatic 11b-HSD1 mRNA expression and adipose activity between lean and obese animals were normalized by gonadectomy, whereas obese gonadectomized animals maintained elevated liver 5a-reductase and had an exaggerated elevation of 5b-reductase activity. It therefore appears that androgens selectively modulate 11b-HSD1 but not hepatic A-ring reductases in obese male rats, thus influencing tissue-specific cortisol availability and action.
As stated above, the activity of the HPA axis, in both basal and stimulated condition, differs according to sex. In rodents, basal ACTH and corticosterone levels, as well as their response to various stimuli, have been found uniformly higher in females than in males. 81, 82 Accordingly, it has been shown that healthy women may be more responsive to CRH 83 or to a combination of CRH and arginine vasopressin (AVP) with respect to ACTH secretion. [84] [85] [86] However, cortisol responses to acute stress challenges have been found to be higher in abdominally obese women 87 and men, 88 compared with their peripheral counterpart. We have recently shown that both normal-weight and obese men had significantly higher ACTH and cortisol concentrations than normalweight and obese women; 16 in contrast, hormone response to CRH plus AVP stimulation was significantly higher in the latter compared with the former (Figure 3 ). Therefore, a sex difference in the activity of the HPA axis still persists even in the presence of obesity and is possibly amplified significantly. At variance, one study 17 performed in healthy male and female volunteers undergoing the CRH stimulation test after 3-5 months of gonadal suppression with leuprolide showed that the hormone response was unexpectedly higher in men than in women. This may suggest that, when sex hormones are suppressed, the relationship is completely overturned, which implies a different role of androgens and oestrogens in the regulation of HPA axis activity. In rats, ovariectomy in fact leads to an attenuated HPA axis response, whereas oestradiol replacement may induce HPA axis stimulation. 89, 90 In healthy young men, short-term oestradiol treatment leads to an enhanced ACTH and cortisol stress response. 91 Androgens, conversely, act on the HPA axis by inhibitory effects. Experiments performed in rats have suggested that basal ACTH release is regulated by a testosterone-dependent effect on AVP and a corticosteronedependent effect on CRH synthesis at the hypothalamic level. 79 In addition, ACTH and corticosterone responses to acute stress in the male rat are increased by gonadectomy, whereas this effect is reversed with testosterone replacement, probably through an androgen receptor-mediated mechanism. 79 The functional cross talk between the HPA axis and sex steroids is, however, bidirectional, with differences according to sex. Several years ago, Bjorntorp 50, 74 proposed the hypothesis that sex hormone imbalance in obesity may be partly dependent on a primary neuroendocrine hyperactivity of the HPA axis. In vitro studies have in fact shown that increased CRH secretion inhibits GnRH secretion. 92, 93 In this way, the association between increased HPA axis activity and low testosterone levels in obese men makes sense, although other factors may be responsible for decreased testosterone in male obesity. 9 However, this mechanism makes it difficult to explain what happens in women with abdominal obesity, who are relatively hyperandrogenic. Hyperactivity of the HPA axis was, however, involved in the development of insulin resistance and compensatory hyperinsulinemia in these women. 9 As occurs in those with polycystic ovary syndrome (PCOS), it could be argued that an insulin-mediated overstimulation of ovarian steroidogenesis by prevailing hyperinsulinemia may occur, insulin being a gonadrotropic hormone, synergizing luteininzing hormone activity, 94 although this is debatable.
Interestingly, conditions of endogenous hypercortisolism are good examples of how the HPA axis may regulate gonadal function differently according to sex. In fact, in men, Cushing's syndrome is associated with reduced gonadotropin levels and low testosterone concentrations, regardless of the extent of the hypercortisolism. 95 On the contrary, women with Cushing's syndrome and mild hypercortisolism may present with androgen excess of both adrenal and ovarian origin and with polycystic ovaries, whereas when severe hypercortisolism is present, the hypothalamicpituitary-gonadal axis may be inhibited, sharing a similar condition to Cushing's syndrome in men. 96 In a recent study, we found that ACTH response to a combined stimulation of the HPA axis with CRH plus AVP was negatively correlated with luteininzing hormone levels in both obese men and women, whereas cortisol response tended to be negatively correlated with the free androgen index in obese ).
Role of glucocorticoids and androgens in obesity R Pasquali et al men, but positively in obese women, 16 suggesting a direct effect of cortisol on excess androgen production in the latter. These hypotheses have been recently supported by the finding that, when compared with BMI-matched nonstressed obese women, women who rapidly developed obesity after major stressful events were characterized by significantly higher UFC (Figure 4 ), androstenedione and free androgen index values (unpublished data). These findings may therefore provide additional explanatory clues to the interaction between the activity of HPA axis and androgens in women, although many more precise data are needed to support this hypothesis.
Association between steroid imbalance, insulin resistance and the metabolic syndrome
In the following part of this review, we will focus on the studies showing an association between abnormalities of the HPA axis and androgens, and the metabolic syndrome, T2D and CVDs.
With alterations of the HPA axis As for Cushing's syndrome, insulin resistance is frequently associated with visceral fat accumulation and increased susceptibility for T2D and CVDs. Although the pathophysiology of the metabolic syndrome is only partially understood, insulin resistance is believed to play a crucial role in this context. 97, 98 Direct evidence in humans is still lacking, but epidemiological data provide strong evidence for a significant positive effect of cortisol on fasting glucose concentrations 99,100 ( Figure 5 ). Other studies have shown a significant association between morning cortisol levels and insulin resistance, hypertension, glucose intolerance and hypertriglyceridemia, with some difference according to sex. 99, 101, 102 It has also been found that increased cortisol levels may be an early feature of essential hypertension. 103 In a study performed in a South Asian cohort, it was recently found that the associations between morning cortisol values and CVD risk factors were stronger than those observed in Caucasian populations, and that they were amplified by adiposity, with some difference between the sexes, suggesting that increased glucocorticoid action may contribute to the prevalence of the metabolic syndrome regardless of ethnicity. 104 These data are in agreement with some studies reporting a significant positive correlation between cortisol response to acute CRH plus AVP stimulation, 105 or nightly UFC excretion 14 and insulin resistance indexes in women with different obesity phenotypes ( Figure 6 ). A dangerous allostatic load has also been associated with metabolic disorders, as a consequence of the failure to turn off of the HPA axis together with the sympathetic activity after chronic stress exposure. 70 Moreover, the reduction of the allostatic load appears to be associated with lower allcause mortality, 106 which indirectly implies a concomitant improvement of most important risk factors for CVDs. As allostatic load is affected by a number of behavioural aspects, strictly linked to human obesity, such as diet, smoking, alcohol consumption and the amount of physical activity, 70 this could therefore explain why the reduction of the allostatic load by lifestyle management has been found to improve the dangerous impact of metabolic disorders. 106 Some evidence from human studies focusing on biological markers of SNS overactivity provides further proof in favour of the complex association between hyperactivity of the stress hormonal systems and metabolic disorders. Brunner et al. 107 found that middle-aged men with the metabolic syndrome were characterized by not only significantly higher UFC and urinary cortisol metabolites, but also high urine normetanephrine, together with more prevalent alterations of inflammatory markers and worsened indices of psychosocial and behavioural parameters. These data support the concept that both neuroendocrine axes are overactive in the presence of the metabolic syndrome. This is in line with our own data obtained in groups of women with 
Control group
Non stress group Stress group Figure 4 Differences in 24-h UFC excretion rate in women who suddenly developed obesity after a stress event (stress group) compared with women in whom obesity developed progressively over time (non-stress group), and normal-weight controls. *Po0.05.
Role of glucocorticoids and androgens in obesity R Pasquali et al different obesity phenotypes who underwent yoimbine infusion to achieve norepinephrine levels similar to those measured after moderate acute stress exposure. When levels of norepinephrine were in a steady state, a CRH plus AVP stimulation test was performed. 68 We found that the HPA response (measured as ACTH and cortisol blood levels) was significantly higher in obese women, particularly those with the abdominal phenotype, than in normal weight controls, which suggests a coordinated role of overactive sympathetic pathways and HPA axis in the response to stress in obesity. 68 Data have recently emerged concerning associations between the HPA axis and the occurrence of atheromatous disease. 20 These studies are hampered by the lack of simple measurement procedures for HPA axis function, which can be applied in large epidemiological studies. Most investigators have therefore relied on fasting plasma cortisol levels, a crude index of HPA axis function. Interestingly, in the Caerphilly Heart Study, Smith et al. 108 reported a positive association between an index of chronic stress, 109,110 the plasma cortisol/testosterone ratio and incident CVD in a large cohort of adult men. In smaller studies, higher plasma cortisol has also been associated with the extent of atheromatous disease quantified by coronary angiography, 111 and predicted mortality in patients with heart failure. 112 Polymorphisms in the glucocorticoid gene have also recently been associated with cardiovascular event rate in population-based European 20 and Australian studies. 113 Given the potential role of increased HPA axis activity in determining insulin resistance and in favouring the development of the metabolic syndrome, a better understanding of the HPA axis function and activity in obese dysmetabolic individuals should be expanded, as recommended recently also by the International Diabetes Federation. 28 With alterations of sex hormones As androgens have an important impact on both glucose and lipid metabolism and on fat homoeostasis, it is likely that androgen imbalance in obesity may have a function in the pathophysiology of the metabolic syndrome and increase the risk of CVDs. 114, 115 Although the few large prospective studies have not confirmed a significant association, crosssectional studies have nonetheless provided some evidence for a linkage between testosterone levels and coronary heart disease (CHD) events in both men and women. 114 One reason for the failure to obtain conclusive information from clinical and epidemiological studies may be partly dependent on the sex-related different behaviour of sex hormones in the presence of obesity. On the other hand, this hypothesis has attracted scientific concern, as low testosterone levels in men and a condition of relative hyperandrogenism in women are associated with abdominal obesity, the metabolic syndrome, insulin resistance and compensatory hyperinsulinemia. It has, accordingly, been speculated that altered testosterone concentrations may be a surrogate of the risk represented by the presence of obesity and associated insulin resistance with T2D and CHD in both women and men, although with some differences. 114, 116 In men, there are studies showing that after adjusting for BMI, fat distribution and insulin resistance, the correlations of major cardiovascular risk factors with testosterone, but not with visceral fat or insulin levels, lost their statistical Role of glucocorticoids and androgens in obesity R Pasquali et al significance. 117, 118 Other studies, however, found that, after adjustment for BMI and WHR, the negative correlation of testosterone with insulin and lipid levels remained statistically significant. 119 It has also been reported that normal testosterone and SHBG levels in males are associated with higher insulin sensitivity and reduced risk for the metabolic syndrome, regardless of body weight and composition. 120 Epidemiological studies have also shown that testosterone is lower in men with T2D with respect to those without it, with a higher prevalence of a hypogonadic state in the former. 116 Lower testosterone levels have also been found in men with impaired glucose tolerance. 121 Low testosterone levels in men have therefore been proposed as a potential component of the metabolic syndrome. 122 Indirectly, this is supported by studies performed in both hypogonadic men and obese subjects providing consistent evidence that subnormal testosterone blood levels are associated with excess visceral fat and insulin resistance, regardless of BMI values. 123, 124 Moreover, suppression of testosterone secretion by long-term administration of a gonadotropin-releasing analogue has been found to increase serum leptin and insulin, which are markers of insulin resistance. 125 In addition, hypotestosteronemia and insulin resistance tend to recover after substantial weight loss. 9 Finally, long-term treatment with testosterone in obese men with high WHR values has been found to selectively decrease visceral fat and significantly improve insulin resistance. 124 Women, particularly those with the abdominal fat distribution, present with the opposite relationships between androgens and obesity, insulin and cardiovascular risk factors. 114 The significant decrease of blood SHBG concentrations, which specifically occurs in women with abdominal obesity, has been found to be an independent risk factor for the development of T2D. 126 Unfortunately, there are relatively few studies investigating the relationship between androgens with insulin resistance and the metabolic syndrome, although there is emerging evidence that high androgen levels may predict cardiovascular risk in women. The paradigm of PCOS is a good example supporting the association between hyperandrogenemia and the metabolic syndrome. Most obese and even normal-weight women with PCOS have insulin resistance and compensatory hyperinsulinemia, which is often associated with central adiposity. 127 In these women, excess androgens show a positive significant correlation with insulin levels and indices of insulin resistance. 94 Owing to its gonadrotropic action, the high levels of insulin in PCOS have a direct pathophysiological role in hyperandrogenism, synergizing with luteininzing hormone to stimulate excess ovarian androgen production. 94 Accordingly, the improvement of the insulin-resistant state, which occurs after hypocaloric diet 128 or insulin sensitizer administration, 129 commonly favours a decrease of androgen levels in women with PCOS. However, androgen excess per se may be responsible for the development of insulin resistance and abdominal obesity. In rats, a moderate increase of testosterone concentrations is in fact followed by a decrease of insulin sensitivity. 130 Similar findings have been reported in rats after exposure to excess androgenic maternal environment. 131 Additional studies performed in non-PCOS postmenopausal women have shown that androgen administration causes insulin resistance and increases visceral fat depots. 132 Moreover, it has been demonstrated that longterm administration of antiandrogens in obese PCOS women improves insulin sensitivity and selectively reduces visceral fat measured by computer topography scan. 133 These findings support the concept that a vicious circle may therefore take place in which insulin and androgen excess influence each other, leading to the development of the PCOS, often characterized by the abdominal fat distribution. Whether this mechanism may also operate in women with abdominal obesity but without PCOS is however uncertain. Women with PCOS also have a higher than expected susceptibility to develop T2D, as well as obesity representing a prerequisite for such an evolution. 134 Moreover, affected PCOS women appear to be more hyperandrogenic and insulin resistant compared with those with normal glucose tolerance. 135 Whether women with PCOS are susceptible to develop more cardiovascular events, particularly coronary events, has been a matter of controversy, in spite of the fact that they often present with multiple cardiovascular risk factors, also including lipid and haemocoagulative alterations and inflammatory factors. 136 Very recently, however, a prospective study was performed in 104 women with clinical features of PCOS defined by a premenopausal history of irregular menses and current biochemical evidence of hyperandrogenemia and 286 controls without a history of irregular menses and hyperandrogenism, participating in the Women's Ischemia Syndrome Evaluation. In this study, it was found that women with clinical features of PCOS were more often diabetic (Po0.0001) and obese (P ¼ 0.005), had the metabolic syndrome (Po0.0001) and more angiographic coronary artery disease (P ¼ 0.04) than women without PCOS. Cumulative 5-year CVD event-free survival was 78.9% for the former versus 88.7% for the latter (P ¼ 0.006). These findings therefore support the concept that hyperandrogenic PCOS women are not only characterized by a high prevalence of cardiovascular risk factors, but also tend to develop more angiographic coronary artery disease and have worsening cardiovascular event-free survival, suggesting the need for risk factor assessment and prevention of CVD in these women. 137 Apart from those performed in PCOS women, very few studies have investigated the relationship between endogenous levels of androgens and CHD or CVDs in women. A recent review 114 reported only two cross-sectional studies on the relationship between circulating testosterone and CHD in non-PCOS women and found that one was positive, whereas the other was negative. However, in the same review, the authors 114 found that all (n ¼ 6) but one cross-sectional study provided consistent evidence for the presence of a strong obesity-independent cluster of CVD risk factors. However, none of the few retrospective
Role of glucocorticoids and androgens in obesity R Pasquali et al studies included in the review found a greater incidence of cardiovascular end points, including stroke as well as myocardial infarction. In particular, in the prospective Rancho Bernardo Study investigating women with and without a history of heart disease at baseline, and focusing on CVD mortality during the follow-up, androgens did not predict death for CVD or CHD during the subsequent 19 years. 138 Therefore, the evidence that increased androgenicity in obese women without PCOS predisposes to CVDs is still weak and controversial. Figure 7 Sex difference in endogenous androgens and risk for T2D: a meta-analysis (reproduced with permission of Ding et al. 116 ; references included in the figure refer to those reported by Ding et al.
116
).
In contrast, the relationship between androgens and T2D in both sexes is of particular interest, and has been consistently investigated in the last decade. The topic was comprehensively assessed in both men and women in a recent meta-analysis including nine cross-sectional as well as three prospective studies 116 ( Figure 7) . Cross-sectional studies included in this review indicated that testosterone levels were significantly lower than normal in diabetic men (À76.6 ng per 100 ml; 95% CI, À99.4 to À53.6) and higher than normal (6.1 ng per 100 ml; 95% CI, 2.3-10.1) in diabetic women. Similarly, prospective studies showed that men with higher testosterone levels (RR, 0.58; 95% CI, 0.39-0.879) had a 42% lower risk of T2D, whereas there was a suggestion that high testosterone levels increased the risk in women (P ¼ 0.06 for sex difference). Conversely, cross-sectional studies found that normal SHBG levels were more protective in women than in men, with prospective studies indicating that women with higher SHBG levels (460 vs o60 nmol l
À1
) had an 80% lower risk of T2D (RR, 0.20; 95% CI, 0.12-0.30), whereas men with high SHBG levels had a 52% lower risk (RR, 0.58; 95% CI, 0.33-0.69). In a more recent prospective study conducted on 6574 women followed up for an average of 10 years, Ding et al. 139 investigated 359 incident cases of T2D matched with 359 controls and found that testosterone (and oestradiol) levels were strongly and positively associated with the risk of T2D, and that the association remained robust even after accounting for other metabolic syndrome components, HbA1c, BMI, family history, lifestyle and reproduction variables. These data therefore further suggest a potential role of androgens in the pathogenesis of T2D in both sexes.
Conclusions and perspectives
The concept that abdominal obesity and associated metabolic and cardiovascular comorbidities may be part of the so-called 'general adaptation syndrome' proposed by Selye 60 years ago has attracted scientific attention in the last 15 years, although the pathophysiology of this relationship in humans is poorly understood. However, prospective data obtained from animal studies support this concept and emphasize the role of the two main stress endocrine systems, the HPA axis and the SNS, in the cascade of events leading to terminal diseases. As originally suggested by Bjorntorp, 13 we support the concept that sex hormone imbalance may have an additional function in this context, taking into consideration that alterations of androgen balance associated with abdominal obesity are part of the pathobiology of sex differences.
Human studies have clearly shown that, in the presence of abdominal obesity, the activity of the HPA axis is increased and the catecholaminergic system is overactivated, particularly in women. An androgen imbalance is also present, with low testosterone levels in male obesity, and a condition of functional hyperandrogenism in female obesity, particularly in the presence of the central phenotype. As discussed in this review, central neuroendocrine mechanisms may operate through activation of the HPA axis, which in turn may alter the hypothalamic-pituitary-gonadal axis according to sex. Moreover, sex hormones may provide different degrees of sensitivity and regulation of the same central stress systems, the HPA axis and the SNS. This may explain different levels of responsiveness to acute and chronic stress challenges in males and females. In the periphery, the altered cortisol/ androgen balance may in turn modify the net lipogenetic/ lipolytic balance in various adipose tissue depots in a sexdependent manner, therefore favouring the development of obesity. Recent studies clearly suggest that alterations of these endocrine systems and the metabolic syndrome are associated. There are also data supporting the concept that high cortisol levels and low androgen levels in men and high testosterone levels in women are predictive of an individual susceptibility to develop T2D. Finally, an altered androgen balance may cooperate with an overactive HPA axis and sympathetic pathways in increasing the individual risk of CVD.
It is to be hoped that future epidemiological studies focused on obesity, the metabolic syndrome and risk factors for T2D and CVDs will include measurement of both androgens and markers of the HPA axis activity to define their coordinated predictive power on metabolic and cardiovascular outcomes. Mechanisms responsible for increased cortisol availability in the presence of obesity, particularly the abdominal phenotype, insulin-resistant states and the metabolic syndrome also need to be investigated in depth, and reliable markers of HPA axis activity should be challenged. In addition, the enigma of sexdependent disparate androgen behaviour associated with obesity remains to be elucidated in depth. Whether greater knowledge in this area will have a therapeutic impact on the treatment of obesity and related metabolic and cardiovascular comorbidites is, however, still uncertain, although this could be an interesting challenge.
